Anti-TIF-1γ Antibody Detection Using a Commercial Kit vs In-House Immunoblot : Usefulness in Clinical Practice
Mariscal, Anaís (Institut d'Investigació Biomèdica Sant Pau)
Milán, Milena (Institut d'Investigació Biomèdica Sant Pau)
Baucells, Andrés (Institut d'Investigació Biomèdica Sant Pau)
Martínez, Maria Angeles (Institut d'Investigació Biomèdica Sant Pau)
Garcia Guillen, Andrea (Institut d'Investigació Biomèdica Sant Pau)
Trallero-Araguás, Ernesto (Hospital Universitari Vall d'Hebron)
Alvarado, Marcelo (Hospital Universitari Vall d'Hebron)
Martinez-Martinez, Laura (Institut d'Investigació Biomèdica Sant Pau)
Alserawan, Leticia (Institut d'Investigació Biomèdica Sant Pau)
Franco-Leyva, Teresa (Institut d'Investigació Biomèdica Sant Pau)
Sanz-Martínez, María Teresa (Hospital Universitari Vall d'Hebron)
Viñas-Giménez, Laura (Hospital Universitari Vall d'Hebron)
Corominas, Hèctor (Institut d'Investigació Biomèdica Sant Pau)
Juarez, Candido (Institut d'Investigació Biomèdica Sant Pau)
Castellvi, Ivan (Institut d'Investigació Biomèdica Sant Pau)
Selva O'Callaghan, Albert (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Anti-TIF-1γ autoantibody detection is important for cancer screening in patients with dermatomyositis. The gold standard for anti-TIF-1γ detection, immunoprecipitation, is only available from a few specialized laboratories worldwide, so commercial ELISA/immunoblot tests have emerged in recent years. To analyze their usefulness in diagnosing cancer-associated dermatomyositis, we compared Euroimmun Euroline profile with our previously validated in-house immunoblot assay with human recombinant TIF-1γ. We included 308 adult patients from Hospital de la Santa Creu I Sant Pau and Vall Hebrón Hospital (Barcelona, Spain) tested for anti-TIF-1γ autoantibodies using the Euroline profile and an in-house immunoblot assay. A total of 27 anti-TIF-1γ were detected by the Euroline and 12 by the in-house assay. Fair agreement was observed between Euroline and the in-house immunoblot Cohen's kappa 0. 3163. Expected prevalence of anti-TIF-1γ autoantibodies was observed for the two methods for dermatomyositis and undifferentiated connective tissue diseases, but unexpectedly high prevalence of anti-TIF-1γ autoantibodies was detected by Euroline compared to the in-house immunoblot for other diseases (16. 5% Euroline vs 0. 8% in-house immunoblot, p<0. 01). The in-house IB compared to Euroline more reliably detected cancer in patients with DM with anti-TIF-1γ antibodies (p=0. 0014 vs p=0. 0502 for in-house immunoblot vs Euroline). We recommend using a second validated method to confirm Euroline-detected anti-TIF-1γ antibodies when the dermatomyositis diagnosis is not definitive. Furthermore, in the context of definite DM diagnosis with negative anti-TIF-1γ antibodies by Euroline and no other myositis specific antibody, is also recommendable to confirm by a second validated method.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Dermatomyositis ; Cancer ; Autoantibody ; Diagnosis ; Immunoassay
Published in:	Frontiers in immunology, Vol. 11 (february 2021) , ISSN 1664-3224

DOI: 10.3389/fimmu.2020.625896
PMID: 33613568

5 p, 380.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles